Medizone Home
×

Cinfa Biotech announces positive top-line data from second clinical study with pegfilgrastim biosimilar candidat

Cinfa Biotech S.L., the biosimilars company of Cinfa Group, today announced positive top-line data from the second clinical trial with its lead development candidate B12019, a biosimilar version of Neulasta ...

Comparator Sourcing – Clinical Trials – Medizone

Medizone campaign: Opening up new dimensions in comparator sourcing for clinical trials. Being a pioneer means having a vision. Medizone as a strategic comparator sourcing partner for clinical trials and ...

Biocad announces the trastuzumab biosimilar approval in Russia

The trastuzumab biosimilar, to be marketed under the trade name HERtiCAD, is the first trastuzumab biosimilar to receive authorization from the Russian regulatory body. The market authorization of the ...

Intas launches Razumab, the first biosimilar to Lucentis

Intas Pharmaceuticals has launched Razumab™, its biosimilar to Lucentis® (Ranibizumab). Intas is the first company globally to develop and launch a biosimilar version of Ranibizumab. Razumab is ...
Pages:«1234»